Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.6K citations

Mixed-phenotype Acute Leukemia, Pathology, Acute Leukemia +18

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym et al. · Blood · 2015 · 1.1K citations · Full text

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Chen Zhao, Alan Chen, Catriona Jamieson et al. · Nature · 2009 · 852 citations · Full text

Tumor Biology, Developmental Biology, Medicine +10

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou et al. · Journal of Clinical Oncology · 2019 · 680 citations · Full text

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 474 citations · Full text